Matsuo K, Ikizler T A, Hoover R L, Nakamoto M, Yasunaga C, Pupim L B, Hakim R M
Department of Medicine, Division of Nephrology, Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232-2372, USA.
Kidney Int. 2000 Feb;57(2):697-708. doi: 10.1046/j.1523-1755.2000.00892.x.
Advanced glycation end product-modified beta2-microglobulin (AGE-beta2m) is an important component of dialysis-related amyloidosis (DRA). Its presence induces monocyte chemotaxis and the release of the proinflammatory cytokines through macrophage activation. Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that also has chemotactic activity for monocytes at very low (0.1 to 10 pg/mL) concentrations and inhibits proinflammatory cytokine production of macrophages. In this study, we investigated the role of TGF-beta in the pathogenesis of DRA.
We performed an immunohistochemical study of DRA tissues (8 cases) to confirm the existence of TGF-betas and their receptors; we also performed a chemotaxis assay of human monocytes as well as enzyme-linked immunosorbent assay (ELISA) of TGF-beta1, tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-1 receptor antagonist (IL-1Ra) in the supernatant of human monocyte-derived macrophage cell culture under varying conditions of incubation with TGF-beta1, AGE-beta2m, and TGF-beta1 antibody additions.
There was positive staining for TGF-betas (types 1, 2, and 3) and their receptors (types I, II, and III) in infiltrated macrophages (CD68+), synovial lining cell, as well as vascular walls around amyloid deposition. AGE-beta2m also induced TGF-beta1 production by macrophages in a dose-dependent manner (410 +/- 80 pg/mL at 12.5 microg/mL, 621 +/- 62 pg/mL at 25 microg/mL, and 776 +/- 62 pg/mL at 50 microg/mL of AGE-beta2m). AGE-beta2m induced significant TNF-alpha and IL-1Ra production by macrophage. The addition of exogenous TGF-beta1 (0.1 to 10 ng/mL) decreased AGE-beta2m-induced TNF-alpha production and increased IL-1Ra production in a dose-dependent fashion. IL-1beta production was not effected by any experimental conditions. In chemotaxis assay, anti-TGF-beta1 antibody (0.1 to 10 microg/mL) attenuated AGE-beta2m-induced monocyte chemotaxis.
These results provide the first evidence to our knowledge for the presence of TGF-beta in DRA tissue, as well as the stimulatory action of AGE-beta2m on tissue macrophages. In turn, TGF-beta suppresses the proinflammatory activation of macrophages, suggesting a dual role for TGF-beta in the inflammatory process of DRA. These observations may provide a pathophysiologic link between TGF-beta and DRA.
晚期糖基化终产物修饰的β2-微球蛋白(AGE-β2m)是透析相关淀粉样变(DRA)的重要组成部分。其存在可诱导单核细胞趋化,并通过巨噬细胞活化释放促炎细胞因子。转化生长因子-β(TGF-β)是一种多功能细胞因子,在极低浓度(0.1至10 pg/mL)时对单核细胞也具有趋化活性,并抑制巨噬细胞的促炎细胞因子产生。在本研究中,我们调查了TGF-β在DRA发病机制中的作用。
我们对DRA组织(8例)进行免疫组织化学研究,以确认TGF-β及其受体的存在;我们还进行了人单核细胞趋化试验,以及在添加TGF-β1、AGE-β2m和TGF-β1抗体的不同孵育条件下,对人单核细胞衍生巨噬细胞培养上清液中的TGF-β1、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)和白细胞介素-1受体拮抗剂(IL-1Ra)进行酶联免疫吸附测定(ELISA)。
在浸润的巨噬细胞(CD68+)、滑膜衬里细胞以及淀粉样沉积周围的血管壁中,TGF-β(1、2和3型)及其受体(I、II和III型)呈阳性染色。AGE-β2m还以剂量依赖性方式诱导巨噬细胞产生TGF-β1(12.5 μg/mL的AGE-β2m时为410±80 pg/mL,25 μg/mL时为621±62 pg/mL,50 μg/mL时为776±62 pg/mL)。AGE-β2m诱导巨噬细胞产生显著的TNF-α和IL-1Ra。添加外源性TGF-β1(0.1至10 ng/mL)以剂量依赖性方式降低AGE-β2m诱导的TNF-α产生,并增加IL-1Ra产生。IL-1β的产生不受任何实验条件的影响。在趋化试验中,抗TGF-β1抗体(0.1至10 μg/mL)减弱了AGE-β2m诱导的单核细胞趋化。
据我们所知,这些结果首次证明了DRA组织中存在TGF-β,以及AGE-β2m对组织巨噬细胞的刺激作用。反过来,TGF-β抑制巨噬细胞的促炎活化,提示TGF-β在DRA炎症过程中具有双重作用。这些观察结果可能提供了TGF-β与DRA之间的病理生理联系。